The hematopoietic growth factors (HGFs) are an important class of biologic molecules which augment production and functional maturation of hematopoietic cells.
Hematopoietic Growth Factors in Oncology represents the latest in a series of texts in the Cancer Treatment and Research series edited by Dr. Steven T. Rosen. This volume brings under a single cover a discussion of the early discoveries, extensive preclinical and clinical investigation, and the validation of these efforts through the successful clinical extension of these discoveries into clinical hematology and oncology practice improving the treatment and quality of life of countless patients.
The text begins with an outstanding review of the biologic, physiologic, and pharmacologic underpinnings of the discoveries, laboratory studies, and early preclinical and clinical development of the hematopoietic growth factors from some of the actual pioneers in these fundamental studies.While the anticipation around development of early-acting hematopoietic growth factors has not been fully realized, developments in granulocyte colony-stimulating factors, the erythropoietic-stimulating agents, and the thrombopoietin factors have in many ways exceeded the expectations of many. The next three parts in this book then highlight the further clinical development and application of the three major categories of the hematopoietic growth factors, by individuals involved in both the pivotal studies and extended clinical trials that have further defined the efficacy and safety of these agents. Current recommendations for clinical application of the hematopoietic growth factors based on practice guidelines from major professional organizations are presented along with the evidence synthesis available on both efficacy and safety.
In the final part of this volume, a number of very important special considerations regarding the use of the hematopoietic growth factors are discussed including their often controversial role in management of patients with acute leukemia and the myelodysplastic syndromes, their efficacy and toxicity in older cancer patients, and the cost and cost-effectiveness of these agents in the prevention and treatment of hematologic complications exemplified by the use of G-CSF for the prevention of febrile neutropenia in patients receiving cancer chemotherapy. The authors emphasize that any comprehensive evaluation of benefits, harms and costs must consider not only the immediate reduction in risk of neutropenic complications in patients receiving cancer chemotherapy but also the potential long-term effects on disease control and survival when treatment intensity is sustained or enhanced with the adjunctive use of the myeloid growth factors.
In total, this represents the most comprehensive compilation available of preclinical and clinical experience related to the development, validation, and clinical application of the hematopoietic growth factors. The editors share the perspective of the individual authors that no aspect of cancer care deserves more attention as well as further clinical research than the treatment and prevention of life-threatening complications of cancer treatment.
Hematopoietic Growth Factors in Oncology represents the latest in a series of texts in the Cancer Treatment and Research series edited by Dr. Steven T. Rosen. This volume brings under a single cover a discussion of the early discoveries, extensive preclinical and clinical investigation, and the validation of these efforts through the successful clinical extension of these discoveries into clinical hematology and oncology practice improving the treatment and quality of life of countless patients.
The text begins with an outstanding review of the biologic, physiologic, and pharmacologic underpinnings of the discoveries, laboratory studies, and early preclinical and clinical development of the hematopoietic growth factors from some of the actual pioneers in these fundamental studies.While the anticipation around development of early-acting hematopoietic growth factors has not been fully realized, developments in granulocyte colony-stimulating factors, the erythropoietic-stimulating agents, and the thrombopoietin factors have in many ways exceeded the expectations of many. The next three parts in this book then highlight the further clinical development and application of the three major categories of the hematopoietic growth factors, by individuals involved in both the pivotal studies and extended clinical trials that have further defined the efficacy and safety of these agents. Current recommendations for clinical application of the hematopoietic growth factors based on practice guidelines from major professional organizations are presented along with the evidence synthesis available on both efficacy and safety.
In the final part of this volume, a number of very important special considerations regarding the use of the hematopoietic growth factors are discussed including their often controversial role in management of patients with acute leukemia and the myelodysplastic syndromes, their efficacy and toxicity in older cancer patients, and the cost and cost-effectiveness of these agents in the prevention and treatment of hematologic complications exemplified by the use of G-CSF for the prevention of febrile neutropenia in patients receiving cancer chemotherapy. The authors emphasize that any comprehensive evaluation of benefits, harms and costs must consider not only the immediate reduction in risk of neutropenic complications in patients receiving cancer chemotherapy but also the potential long-term effects on disease control and survival when treatment intensity is sustained or enhanced with the adjunctive use of the myeloid growth factors.
In total, this represents the most comprehensive compilation available of preclinical and clinical experience related to the development, validation, and clinical application of the hematopoietic growth factors. The editors share the perspective of the individual authors that no aspect of cancer care deserves more attention as well as further clinical research than the treatment and prevention of life-threatening complications of cancer treatment.
Contents
Part I Background: Biology, Physiology, and Pharmacology
- 1 Introduction to the Hematopoietic Growth Factors
- 2 Early-Acting Hematopoietic Growth Factors: Biology and Clinical Experience
- 3 Granulocyte Colony-Stimulating Factors
- 4 Erythropoiesis-Stimulating Agents
- 5 Thrombopoietin Factors
Part II The Colony-Stimulating Factors
- 6 Cyclic and Chronic Neutropenia
- 7 The Myeloid Growth Factors
- 8 Meta-Analysis of Randomized Controlled Trials of Granulocyte Colony-Stimulating Factor Prophylaxis in Adult Cancer Patients Receiving Chemotherapy
- 9 Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy
- 10 Granulocyte Colony-Stimulating Factors and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Part III The Erythroid-Stimulating Agents
- 11 Do Erythropoietic-Stimulating Agents Relieve Fatigue? A Review of Reviews
- 12 Randomized Controlled Trials of the Erythroid-Stimulating Agents in Cancer Patients
- 13 Ten Years of Meta-analyses on Erythropoiesis-Stimulating Agents in Cancer Patients
- 14 Clinical Practice Guidelines for the Use of Erythroid-Stimulating Agents: ASCO, EORTC, NCCN
Part IV The Thrombopoietic Agents
- 15 Thrombocytopenia and Platelet Transfusions in Patients with Cancer
- 16 Romiplostim
- 17 Eltrombopag
Part V Special Considerations
- 18 The Hematopoietic Growth Factors in Acute Leukemia: US Perspective
- 19 The Hematopoietic Growth Factors in Acute Leukemia: A European Perspective
- 20 The Hematopoietic Growth Factors in theMyelodysplastic Syndromes
- 21 Hematopoietic Growth Factors in Older Cancer Patients
- 22 The Economics of the Hematopoietic Growth Factors
Index
Product Details
- Author: Gary H. Lyman and David C. Dale
- Hardcover: 433 pages
- Publisher: Springer; 1st Edition. (November 8, 2010)
- Language: English
- ISBN-10: 144197072X
- ISBN-13: 978-1441970725